COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,686 Articles (22,913 medRxiv, 8,773 bioRxiv)

Most recent first Previous |  Page 1816: Articles 18151-18160  | Next

A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets
Kratzel, A., Kelly, J. N., Brueggemann, Y., Portmann, J., V'kovski, P., Todt, D., Ebert, N., Steinmann, E., Dijkman, R., Zimmer, G., Pfaender, S., Thiel, V.
10.1101/2021.02.24.432634 — Posted: 2021-02-24
Targeted Drug Repurposing Against the SARS-CoV-2 E Channel Identifies Blockers With in vitro Antiviral Activity
Tomar, P. P. S., Krugliak, M., Arkin, I. T.
10.1101/2021.02.24.432490 — Posted: 2021-02-24
The nonstructural protein 5 of coronaviruses antagonizes GSDMD-mediated pyroptosis by cleaving and inactivating its pore-forming p30 fragment
Shi, F., Lv, Q., Wang, T., Xu, J., Xu, W., Shi, Y., Fu, X., Yang, T., Yang, Y., Zhuang, L., Fang, W., Gu, J., Li, X.
10.1101/2021.02.23.432418 — Posted: 2021-02-24
Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape
Brown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., Hassard, J., Moshe, M., Singanayagam, A., Burgoyne, T., PHE Virology Consortium, , Barclay, W. S.
10.1101/2021.02.24.432576 — Posted: 2021-02-24
Targeting of the NLRP3 Inflammasome for early COVID-19
Marchetti, C., Mould, K., Tengesdal, I. W., Janssen, W. J., Dinarello, C. A.
10.1101/2021.02.24.432734 — Posted: 2021-02-24
Mandatory public health measures for COVID-19 are associated with improved mortality, equity and economic outcomes
Lundberg, B., McDonald, K.
10.1101/2021.02.11.21251580 — Posted: 2021-02-24
COVID-19 in New York state: Effects of demographics and air quality on infection and fatality
Mondal, S., Chaipitakporn, C., Kumar, V., Wangler, B., Gurajala, S., Dhaniyala, S., Sur, S.
10.1101/2021.02.22.21252262 — Posted: 2021-02-24
Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination
Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Figueiredo, J. C., Van Eyk, J., Braun, J., Cheng, S., Sobhani, K.
10.1101/2021.02.23.21252230 — Posted: 2021-02-24 Discussion: Onsite
Associations Between Google Search Trends for Symptoms and COVID-19 Confirmed and Death Cases in the United States
Abbas, M., Morland, T. B., Hall, E. S., El-Manzalawy, Y.
10.1101/2021.02.22.21252254 — Posted: 2021-02-24
SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Bohehm, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., Taube, R.
10.1101/2021.02.22.21252002 — Posted: 2021-02-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).